The use of Tranexamic Acid in Hip Fracture Surgery (HipFrac TXA)

South West PeninsulaInjuries and Accidents, Musculoskeletal
Start Date: 1 Sep 2015

The use of Tranexamic Acid in Hip Fracture Surgery (HipFrac TXA)

Background

Tranexamic acid (TXA) is an inexpensive and easily administered drug that can be used to prevent or treat excessive blood loss after trauma or surgery. PenCLAHRC have previously been involved in the TXA in Trauma project, working with the South West Ambulance Service Trust (SWAST) to introduce the use of TXA in ambulance crews across the South West. As a result of this work, the procedure has now been rolled out across all ambulance services in England and is included in UK National Guidelines for the Joint Royal Colleges Ambulance Liaison Committee.

Surgical treatment of fragility hip fractures is challenging, being associated with high morbidity, mortality and significant cost that is mostly related to length of hospital stay, rehabilitation and social care. The majority of patients are elderly and frail, making them more susceptible to blood loss, with transfusions required in as many as 25% to 40% of cases. Complications associated with this include anaemia (deficiency of red blood cells) and hypovolemia (decreased volume of circulating blood in the body), as well as an increased risk of other problems such as infection and extended length of stay in hospital.

It is therefore important to reduce, as far as possible, blood loss and the need for blood transfusions during hip fracture surgery in order to improve outcomes for elderly patients. Whilst there is growing evidence to support the routine use of TXA in major elective orthopaedic surgery that includes more elderly and frail subgroups of patients, no definitive study has been carried out on the benefits and potential downsides of this drug in hip fracture care.

Project Aims

This study seeks to establish whether treatment with TXA prior to operation improves the outcomes of elderly patients undergoing hip fracture surgery. The main aims are:

  • To understand the extent of the current use of TXA in hip fracture surgery and clarify whether use of the drug may be linked to reduced transfusion rates, improved recovery times and reduced stays in hospital
  • Develop a study design to evaluate the use of TXA in hip fracture surgery

Audit of hip fracture operation data

The team has conducted an audit of data from 618 hip fracture operations that took place in the Royal Devon & Exeter Hospital in 2014. This allowed identification of the types of fractures that are operated on and those that were most susceptible to requiring transfusion either during or after surgery.

The next steps are to include hip fracture operation data from 2015 to this audit to track surgery and transfusion trends over time

Development of study design for evaluating TXA use in hip fracture surgery

The team are planning to design a study that would help them evaluate the use of TXA in hip fracture surgery, in particular whether or not hip fracture patients require a blood transfusion within 7 days of surgery, the amount of transfused blood, the occurrence of blood clots in the vein and mortality within 90 days of surgery. A funding application will be developed to support the design and conduct of a research trial in this area.

Contact 
O.C.Ukoumunne@exeter.ac.uk
Dr Obioha Ukoumunne